Sign up Australia
Proactive Investors - Run By Investors For Investors

Cyclopharm unveils new nuclear medicine technology

Cyclopharm unveils new nuclear medicine technology

Cyclopharm (ASX: CYC) is heading for regulatory approvals for its newly developed proprietary patented technology, Ultralute, that will enable nuclear medicine departments to dramatically improve their operating efficiencies and health outcomes for patients.

The Ultralute technology extends the useful life of Mollybdenum-99 generators, the world’s most common nuclear medicine radioisotope and a precursor to the Technetium-99m (Tc-99m) isotope, by up to an additional 50%.

Tc-99m is the primary isotope used in diagnostic imaging throughout the world accounting for about 80% of all procedures performed in nuclear medicine today.

Applications include cardiac, bone, liver, brain, renal and lung imaging.

Initial testing and prototype designs of the Ultralute technology have provided highly positive results.

Cyclopharm is now moving toward the regulatory approval process and at the same time has entered into discussions with potential commercial partners.

The company had around A$2.3 million in cash at the end of December 2012.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.



Register here to be notified of future CYC Company articles
View full CYC profile View Profile

Cyclopharm Timeline

Related Articles

Microbes
April 16 2017
Stephen O’Hara created Opti as a company all by himself in 2012 as a business focused on the rapidly growing microbiome space, which harnesses the positive benefits of microbes that live on the human body
shutterstock_127456451.jpg
March 30 2017
PIFA Heparin PF/4 - a diagnostic test for allergic reactions to blood thinning agent Heparin - achieved an 85% jump in sales in 2016
stem cell
June 12 2017
"With multiple value upside triggers ahead, including imminent maiden revenues from CellPlan, I very much look forward to the opportunities ahead" - CEO João Andrade

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use